Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with...
China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149
China’s Center for Drug Evaluation (CDE) released its 2025 Annual Drug Review Report, revealing record...
Shanghai Implements Fixed-Amount Reimbursement Model for 11th NVBP Drugs – Patients Bear Excess Costs Above Winning Prices
The Shanghai Municipal Healthcare Security Bureau issued the “Notice on Optimizing Payment Coordination for the...
Novo Nordisk’s Wegovy Shows 21.6% Weight Loss in Early Responders – OASIS 4 Subgroup Analysis Reveals Clinically Meaningful Benefits Across Patient Populations
Novo Nordisk A/S (NYSE: NVO) presented new subgroup analyses from the Phase III OASIS 4...
Ab&b Bio-Tech Launches Phase I/II Trial of Recombinant RSV Vaccine – CHO Cell-Derived Adjuvanted Candidate Shows Enhanced Pre-F Protein Expression and Stability
Ab&b Bio-Tech Co., Ltd. (HKG: 2627) announced the initiation of a Phase I/II clinical study...
TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections
TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock...
Kanghong Pharma’s Gene Therapy KHN921 Receives FDA Approval for Hypertrophic Cardiomyopathy Trial – AAV9 Vector Targets MYBPC3 Mutations with Potential One-Time Treatment
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced that its subsidiary Chengdu Origen Biotechnology...
InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial – Novel Oral IL-17AA/AF Inhibitor Shows Promise for Autoimmune Diseases
InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study...
Hengrui Pharma Launches Phase Ib/II Trial of Novel Triple Combination Therapy – SHR-3821 with Adebrelimab and Reltirafusp Alfa Targets Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received regulatory approval...
BeOne Medicines’ BCL2 Inhibitor Beqalzi (Sonrotoclax) Receives FDA Fast Track for Relapsed Mantle Cell Lymphoma – 52% Response Rate in Phase I/II Study
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that its self-developed...
China’s NHSA Unveils Five-Year Medical Insurance Fund Supervision Plan (2026–2030) – AI-Powered Oversight to Combat Fraud Across Healthcare Ecosystem
China’s National Healthcare Security Administration (NHSA) released its comprehensive “Five-Year Action Plan for Medical Insurance...
Zhongsheng Pharma’s Onradivir (Anruiwei) Receives NMPA Review Acceptance for Pediatric Influenza A Indication – Phase III Data Shows Favorable Efficacy vs. Tamiflu
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...
Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer – Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential
Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China’s...
Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196) announced a strategic licensing agreement with South...
Shanghai Henlius Biotech Doses First Patient in Phase I Trial of HLX97 – Novel KAT6A/B Inhibitor for Advanced Solid Tumors
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...
Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform
Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading...
Eli Lilly Reports Long-Term Weight Loss Maintenance with Foundayo and Lower-Dose Zepbound in Phase 3 Trials
Eli Lilly and Company (NYSE: LLY) announced on May 12, 2026, detailed results from two...
Legend Biotech Reports 56% Q1 Revenue Growth to $305M, Driven by Carvykti Sales Surge and J&J Milestone Payment
Legend Biotech Corporation (NASDAQ: LEGN) reported first-quarter 2026 revenue of USD 305 million, representing 56%...
Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms
Shanghai Immunocan Biotech Co., Ltd. announced the successful completion of a RMB 250 million (USD...
Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...